Hepatotoxicity
Nov
2026
Description
This session covers drug-induced liver injury across multiple contexts — statins, checkpoint inhibitors, acetaminophen, and GLP-1 agonists — using registry data, organoid models, and AI-based case triage tools.
Presentations
2:00 PM
- 2:15 PM
Convention Center - Bluebird Ballroom 3DEF
High-Throughput Drug-Induced Liver Injury Risk Prediction Using Morphological Profiling and Machine Learning in Patient-Derived Human Liver Organoids
Jonathan Z Sexton, PhD | Abstract Presenter
2:15 PM
- 2:30 PM
Convention Center - Bluebird Ballroom 3DEF
Novel acetaminophen formulation at supratherapeutic doses with a favorable human liver safety profile: Preventing toxic metabolite formation
Yuhan Lin, phD | Abstract Presenter
2:30 PM
- 2:45 PM
Convention Center - Bluebird Ballroom 3DEF
A Semi-Automated Artificial Intelligence (AI) Based Algorithm to Prioritize Potential Drug Induced Liver Injury (DILI) Cases from Clinical Trials for Human Clinical Review
Aaron Waddell, PhD | Abstract Presenter
2:45 PM
- 3:00 PM
Convention Center - Bluebird Ballroom 3DEF
Liver function stability following yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma: results from the DOORwaY90 Study (NCT04736121)
Sudha Kodali, MD, MSPH | Abstract Presenter
3:00 PM
- 3:15 PM
Convention Center - Bluebird Ballroom 3DEF
Novel genetic variants associated with immune-mediated liver injury from checkpoint inhibitors: Results from the DILIN Registry and an independent cohort
Linnea Swanson, MD | Abstract Presenter
3:15 PM
- 3:30 PM
Convention Center - Bluebird Ballroom 3DEF
Additional Safety and Efficacy Results from HELIOS: A Phase 2, Open-Label, Long-Term Extension Study of Bitopertin in Erythropoietic Protoporphyria
Bruce Wang, MD | Abstract Presenter
